At Mineralys, we are advancing the clinical development of lorundrostat in people with aldosterone-driven hypertension and beyond

Science Overview

Lorundrostat is a highly selective aldosterone synthase inhibitor.

Lorundrostat Clinical Trials

TRIAL

INDICATION

PHASE 1

PHASE 2

PHASE 3

TARGET-HTN

COMPLETED

Hypertension

PROOF OF CONCEPT

A randomized, double-blind, placebo-controlled, dose-ranging phase 2 trial that evaluated the efficacy, safety, and tolerability of lorundrostat in adults with uncontrolled hypertension, including treatment-resistant hypertension.

ADVANCE-HTN

FULLY ENROLLED

Hypertension

PIVOTAL

An ongoing, randomized, double-blind, placebo-controlled, parallel arm, multicenter, pivotal phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat administered on a background of a standardized antihypertensive medication regimen in adults with uncontrolled hypertension, including treatment-resistant hypertension.

LAUNCH-HTN

FULLY ENROLLED

Hypertension

PIVOTAL

An ongoing, randomized, double-blind, placebo-controlled, parallel arm, multicenter, phase 3 trial to evaluate the blood pressure-lowering effects of lorundrostat in adults with uncontrolled hypertension, including treatment-resistant hypertension, who are taking 2-5 antihypertensive medications (one of which must be a thiazide or thiazide-like diuretic).

HYPERTENSION WITH CKD

Hypertension

PROOF OF CONCEPT

An ongoing randomized, crossover, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of lorundrostat alone and in combination with sodium-glucose cotransporter-2 inhibitors in adults with hypertension and chronic kidney disease with albuminuria.

OPEN-LABEL EXTENSION

Hypertension

OPEN-LABEL EXTENSION

An ongoing open-label extension study to evaluate the long-term efficacy, safety, and tolerability of lorundrostat in adults with uncontrolled hypertension, including treatment-resistant hypertension.

Science Overview

Lorundrostat is an aldosterone-reduction therapy with highly selective inhibition of aldosterone synthase.

At Mineralys, we are advancing the clinical development of lorundrostat in people with aldosterone-driven hypertension and beyond ​

Science Overview

Lorundrostat Clinical Trials

TRIAL

INDICATION

PHASE 1

PHASE 2

PHASE 3

TARGET-HTN

COMPLETED

Hypertension

PROOF OF CONCEPT

ADVANCE-HTN

FULLY ENROLLED

Hypertension

PIVOTAL

LAUNCH-HTN

FULLY ENROLLED

Hypertension

PIVOTAL

HYPERTENSION WITH CKD

Hypertension

PROOF OF CONCEPT

OPEN-LABEL EXTENSION

Hypertension

OPEN-LABEL EXTENSION

Science Overview

Lorundrostat Clinical Trials

PHASE 1

PHASE 2

PHASE 3

TARGET-HTN

COMPLETED

Hypertension

ADVANCE-HTN

FULLY ENROLLED

Hypertension

LAUNCH-HTN

FULLY ENROLLED

Hypertension

HYPERTENSION WITH CKD

Hypertension

OPEN-LABEL EXTENSION

Hypertension

© 2024 Mineralys Therapeutics, Inc.

© 2024 Mineralys Therapeutics, Inc.

At Mineralys, we are advancing the clinical development of lorundrostat in people with aldosterone-driven hypertension and beyond